Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL25253575 | 0.86 | PDE10A (0.33) | PDE10ATRPV1 | |
| Formic Acid SCHEMBL30467685 | 0.86 | PDE10A (0.33) | PDE10ATRPV1 | |
| SCHEMBL25244081 | 0.85 | PDE10A (0.39) | PDE10A | |
| SCHEMBL24252270 | 0.84 | PDE10A (0.36) | PDE10ATRPV1 | |
| SCHEMBL26771225 | 0.82 | PDE10A (0.34) | PDE10ATRPV1 | |
| SCHEMBL25209996 | 0.79 | CDK9 (0.30) | — | |
| SCHEMBL25245402 | 0.77 | — | — | |
| SCHEMBL25212150 | 0.75 | SCN9A (0.37) | PDE10A | |
| SCHEMBL25213122 | 0.74 | PDE10A (0.39) | PDE10A | |
| SCHEMBL25217989 | 0.74 | PDE10A (0.32) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | PDE10A 1950/4885TRPV1 3867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.